2024-03-29T10:44:17Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_80EDD64A446F
2024-03-23T02:36:39Z
serval:BIB_80EDD64A446F
Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.
10.1016/j.clgc.2016.06.011
27450512
000419212000003
Papazoglou
D.
author
Wannesson
L.
author
Berthold
D.
author
Cathomas
R.
author
Gillessen
S.
author
Rothermundt
C.
author
Hasler
L.
author
Winterhalder
R.
author
Barth
A.
author
Mingrone
W.
author
Nussbaum
C.U.
author
von Rohr
L.
author
von Burg
P.
author
Schmid
M.
author
Richner
J.
author
Baumann
S.
author
Kühne
R.
author
Stenner
F.
author
Rothschild
S.I.
author
article
2017-06
2017-06
Clinical genitourinary cancer
1938-0682
1558-7673
journal
15
3
e315-e323
Aged
Antineoplastic Agents/administration & dosage
Antineoplastic Agents/therapeutic use
Humans
Male
Phenylthiohydantoin/administration & dosage
Phenylthiohydantoin/analogs & derivatives
Phenylthiohydantoin/therapeutic use
Prognosis
Prostatic Neoplasms, Castration-Resistant/drug therapy
Retrospective Studies
Survival Analysis
Taxoids/therapeutic use
Treatment Outcome
Abiraterone
Androgen receptor antagonist
Antihormonal drugs
PSA
Treatment sequence
eng
60_published
peer-reviewed
Publication types: Journal Article
Publication Status: ppublish